Sai Parenteral IPO: Subscribed 43% on Day 3, Should You Invest?

Introduction to Sai Parenteral's IPO

Sai Parenteral Limited's initial public offering (IPO) has garnered a subscription of 43% by the morning of its third and final day of bidding, March 26, 2026. The pharmaceutical formulations company aims to raise approximately ₹409 crore through this public issue. The offering has seen a mixed response from different investor categories, with non-institutional investors showing strong interest while retail participation has been notably subdued. The IPO, which opened for subscription on March 24, is set to close on March 27, 2026.

Subscription Journey: A Day-by-Day Account

The IPO experienced a slow start on its opening day, recording only a 4% subscription. Bids were received for just 3.35 lakh shares against the total offer of 75.22 lakh shares. Retail investors subscribed to only 3% of their allotted quota, while the non-institutional investor (NII) portion was subscribed 15%. Qualified Institutional Buyers (QIBs) did not place any bids on the first day.

Momentum picked up slightly on the second day, with the overall subscription reaching 42%. This increase was primarily driven by the NII category, which was oversubscribed at 1.05 times. The QIB portion saw some activity, reaching 60% subscription, but the retail segment remained sluggish at just 5%.

By 10:45 am on the third and final day, the total subscription stood at 43%. The NII portion was oversubscribed at 1.08 times, and the QIB quota remained at 60%. However, retail investor interest saw only a marginal increase, with their portion subscribed to just 7%.

Detailed Subscription Status (Day 3)

The demand for shares has been uneven across investor segments. Non-institutional investors have led the bidding, ensuring their portion was fully covered. In contrast, the response from retail investors has been lukewarm throughout the subscription period.

Grey Market Premium and Listing Expectations

Currently, the Sai Parenteral IPO commands no Grey Market Premium (GMP). A zero GMP indicates that the shares are not trading at any premium in the unofficial market, suggesting expectations of a flat or muted listing. It is important for investors to note that GMP is an informal indicator and does not guarantee the stock's listing price. Market sentiment and subscription figures on the final day can influence the premium.

IPO Structure and Key Details

The company has set the price band for its IPO at ₹372 to ₹392 per equity share. The total issue size is ₹408.79 crore, which comprises a fresh issue of 0.73 crore shares aggregating to ₹285 crore and an offer for sale (OFS) of 0.32 crore shares worth ₹123.79 crore by existing shareholders. Ahead of the IPO, the company successfully raised ₹122.63 crore from five anchor investors, including Morgan Stanley Asia and Kotak Mahindra Life Insurance.

Utilization of IPO Proceeds

The net proceeds from the fresh issue of ₹285 crore are earmarked for specific corporate purposes to fuel the company's growth. The funds will be allocated towards capacity expansion, research and development, debt repayment, and working capital needs.

• Capacity Expansion: ₹110.8 crore will be used for expanding and upgrading manufacturing facilities.
• New R&D Centre: ₹18 crore is allocated for establishing a new research and development center.
• Debt Repayment: ₹14.3 crore will be utilized for the repayment or prepayment of certain borrowings.
• Working Capital: ₹33 crore will fund the company's working capital requirements.
• Subsidiary Investment: ₹35.64 crore will be invested in its subsidiary for a proposed acquisition.

Company Overview and Analyst Perspective

Sai Parenteral Limited operates in the branded generic formulations and Contract Development and Manufacturing Organisation (CDMO) sectors. Its product portfolio includes injectables, tablets, capsules, and ointments across various therapeutic areas. The company aims to increase the revenue share from its high-margin injectables segment.

Brokerage firm SBI Securities has issued a 'Subscribe' rating for the issue with a long-term perspective. The brokerage noted that the company's valuation, at a P/E multiple of 88.2x based on FY25 proforma earnings, appears to be at a premium compared to its peers. However, it highlighted the significant growth opportunity presented by the 451 dossiers of Noumed Pharmaceuticals as a key positive factor.

Conclusion

The Sai Parenteral IPO has seen a modest subscription, primarily supported by non-institutional investors. The lack of retail enthusiasm and a zero grey market premium suggest a cautious market sentiment towards the issue. However, the company's strategic use of funds for expansion and R&D, coupled with a positive long-term outlook from analysts, presents a mixed picture for potential investors. The final subscription figures and the subsequent listing performance will be closely watched.